Gene therapy in Duchenne muscular dystrophy

Brain and Development

Volumn 18, Issue 5, 1996, Pages 357-361

  Inui, Koji ^a   Okada, Shintaro ^a   Dickson, Gorge ^b  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Duchenne muscular dystrophy; Dystrophin gene; Gene therapy; Mdx mouse; Transgenic mice

Indexed keywords

COMPLEMENTARY DNA; DYSTROPHIN; PLASMID DNA;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXPRESSION VECTOR; GENE THERAPY; GENETIC TRANSCRIPTION; MORPHOLOGY; MOUSE; MUSCLE; NONHUMAN; PLANT GROWTH; PLASMID; RETROVIRUS; SHORT SURVEY; SKELETAL MUSCLE; TRANSGENIC MOUSE;

EID: 0030249603     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/0387-7604(96)00043-5     Document Type: Review

References (47)

1. 1. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987; 50: 509-17.
2. 2. Hoffman E P, Brown R H Jr, Kunkel L M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-28.
3. 3. Chamberlain JS, Gibbs RA, Ranier JE, Caskey CT. Multiple PCR for the diagnosis of Duchenne muscular dystrophy. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds. PCR protocols: a guide to methods and applications. New York/London: Academic Press, 1990: 272-81.
4. 4. Beggs AH, Koenig M, Boyce FM, Kunkel LM. Detection of 98% of DMD/BMD gene deletion by polymerase chain reaction. Hum Genet 1990; 86: 45-8.
5. 5. Darras BT. Molecular genetics of Duchenne and Becker muscular dystrophy. J Pediatr 1990; 117: 1-15.
6. 6. Partridge TA. Invited review: myoblast transfer: a possible therapy for inherited myopathies? Muscle Nerve 1991; 14: 197-212.
7. 7. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-60.
8. 8. Morgan RA, Anderson WF. Human gene therapy. Annu Rev Biochem 1993; 62: 191-217.
9. 9. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984; 81: 1189-92.
10. 10. England SB, Nicholson LVB, Johnson MA, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990; 343: 180-2.
11. 11. Wells DJ, Wells KE, Walsh FS, et al. Human dystrophin expression corrects the myopathic phenotype in transgenic mdx mice. Hum Mol Genet 1992; 1: 35-40.
12. 12. Cox GA, Cole NM, Matsumura K, et al. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature 1993; 364: 725-9.
13. 13. Lee CC, Pons F, Jones PG, et al. Mdx transgenic mouse: Restoration of recombinant dystrophin to the dystrophic muscle. Hum Gene Ther 1993; 4: 273-81.
14. 14. Wells DJ, Wells KE, Asante EA, et al. Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Hum Mol Gent 1995; 4: 1245-50.
15. 15. Phelps SF, Hauser MA, Cole NM, et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995; 4: 1251-8.
16. 16. Cox GA, Sunada Y, Campbell KP. et al. Dp 71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nat Genet 1994; 8: 333-8.
17. 17. Greenberg DS, Sunada Y, Campbell KP, Yaffe D, Nudel U. Exogenous Dp71 restores the levels of dystrophin associated proteins but does not alleviate muscle damage in mdx mice. Nat Genet 1994; 8: 340-4.
18. 18. Thomason DB, Booth FW. Stable incorporation of a bacterial gene into adult rat skeletal muscle in vivo. Am J Physiol 1991; 258: C578-81.
19. 19. Dunckley M G, Wells J D, Walsh F S, Dickson G. Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse in vivo. Hum Mol Genet 1993; 2: 717-23.
20. 20. Nancy S, Edgar K, Wilson E, et al. Recombinant retroviral vector delivered intramuscularly localizes to the site of injection in mice. Hum Gene Ther 1994; 5: 693-9.
21. 21. Ragot T, Vincent N, Chafey P, et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993; 361: 647-50.
22. 22. Vincent N, Ragot T, Gilgenkrantz H, et al. Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat Genet 1993; 5: 130-4.
23. 23. Acsadi G, Jani A, Massie B, et al. A different efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. Hum Mol Genet 1994; 3: 579-84.
24. 24. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-8.
25. 25. Dickson G, Love DR, Davis KE, Wells KE, Piper TA, Walsh FS. Human dystrophin gene transfer: production and expression of a functional recombinant DNA-based gene. Hum Genet 1991; 88: 53-8.
26. 26. Acsadi G, Dickson G, Love DR, et al. Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature 1991; 352: 815-8.
27. 27. Davis HL, Jasmin B. Direct gene transfer into mouse diaphragm. FEBS Lett 1993; 333: 146-50.
28. 28. Davis HL, Demeneix BA, Quantin B, Coulombe J, Whalen RG. Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. Hum Gene Ther 1993; 4: 733-40.
29. 29. Vitadello M, Schiaffino MV, Picard A, Scarpa M, Schiaffino S. Gene transfer in regenerating muscle. Hum Gene Ther 1994; 5: 11-8.
30. 30. Trivedi RA, Dickson G. Liposome-mediated gene transfer into normal and dystrophin-deficient mouse myoblasts. J Neurochem 1995; 64: 2230-8.
31. 31. Kaneda Y. Virus (sendai virus envelopes)-mediated gene transfer. In: Cellis JE ed. Cell biology: a laboratory handbook. Vol 3. New York: Academic Press, 1994: 50-7.
32. 32. Tomita N, Higaki J, Morishita K, et al. Direct in vivo gene introduction into rat kidney. Biochem Biophys Res Commun 1992; 186: 129-34.
33. 33. Morishita R, Gibbons GH, Kaneda Y, et al. Novel and effective gene transfer technique for the study of vascular renin angiotensin system. J Clin Invest 1993; 91: 2580-5.
34. 34. Yanagihara I, Inui K, Dickson G, et al. Expression of full-length human dystrophin cDNA in mdx mouse muscle by HVJ-liposome injection. Gene Ther 1996 (in press)
35. 35. Tinsley JM, Davis KE. Utrophin; a potential replacement for dystrophin? Neuromusc Disord 1993; 3: 537-9.
36. 36. Pons F, Robert A, Marini JF, Leger LL. Does utrophin expression in muscles of mdx mice during postnatal development functionally compensate for dystrophin deficiency? J Neurol Sci; 122: 162-70.
37. 37. Salminen A, Elson HF, Mickley LA, Fojo AT, Gottesman MM. Implantation of recombinant rat myocytes into adult skeletal muscle: a potential gene therapy. Hum Gene Ther 1991 2; 15-26.
38. 38. Choi J, Costa ML, Mermelstein CS, Chagas C, Holtzer S, Holtzer H. MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. Proc Natl Acad Sci USA 1990; 87: 7988-92.
39. 39. McDouall RM, Dunn MJ, Dubowitz V. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci 1990; 99: 199-217.
40. 40. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16: 193-208.
41. 41. Gorospe JRM, Tharp MD, Hinckley J, Kornegay JN, Hoffman EP. A role for mast cells in the progression of Duchenne muscular dystrophy? Correlation in dystrophin-deficient humans, dogs, and mice. J Neurol Sci 1994; 122: 44-56.
42. 42. Granchelli JA, Pollina C, Hudecki MS. Duchenne-like myopathy in double-mutant mdx mice expressing exaggerated mast cell activity. J Neurol Sci 1995; 131: 1-7.
43. 43. Bernasconi P, Torchiana E, Confalonieri P, et al. Expression of transforming growth factor-β1 in dystrophic patient muscles correlates with fibrosis. J Clin Invest 1995; 96: 1137-44.
44. 44. Morishita R, Gibbons GH, Horiuchi M, et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995; 92: 5855-9.
45. 45. Minutes from June 8-9, 1995 Recombination DNA advisory committee meeting. Hum Gene Ther 1996; 7: 417-57.
46. - immuno-deficient patients. Science 1995; 270: 470-5.
47. - SCID: Initial trial results after 4 years. Science 1995; 270: 475-9.